| Literature DB >> 35433600 |
Waldecy Rodrigues1,2, Humberto da Costa Frizzera1, Daniela Mascarenhas de Queiroz Trevisan1, David Prata1, Geovane Rossone Reis2, Raulison Alves Resende3.
Abstract
On May 10, 2021, Brazil ranked second in the world in COVID-19 deaths. Understanding risk factors, or social and ethnic inequality in health care according to a given city population and political or economic weakness is of paramount importance. Brazil had a seriousness COVID-19 outbreak in light of social and economic factors and its complex racial demographics. The objective of this study was to verify the odds of mortality of hospitalized patients during COVID-19 infection based on their economic, social, and epidemiological characteristics. We found that odds of death are greater among patients with comorbidities, neurological (1.99) and renal diseases (1.97), and immunodeficiency disorders (1.69). While the relative income (2.45) indicates that social factors have greater influence on mortality than the comorbidities studied. Patients living in the Northern macro-region of Brazil face greater chance of mortality compared to those in Central-South Brazil. We conclude that, during the studied period, the chances of mortality for COVID-19 in Brazil were more strongly influenced by socioeconomic poverty conditions than by natural comorbidities (neurological, renal, and immunodeficiency disorders), which were also very relevant. Regional factors are relevant in mortality rates given more individuals being vulnerable to poverty conditions.Entities:
Keywords: COVID-19; economic factors; mortality in hospitalized; regional factors; social factors
Mesh:
Year: 2022 PMID: 35433600 PMCID: PMC9008306 DOI: 10.3389/fpubh.2022.856137
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Flowchart of the SIVEP-Gripe database used in this analysis. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SIVEP-Gripe, Influenza Epidemiological Surveillance Information System.
Figure 2(A,B) Distribution of absolute number of cases among Brazilian states and the Federal District, and number of cases per 100,000 inhabitants. Cases = 840201. AC, Acre; AL, Alagoas; AM, Amazonas; AP, Amapá; BA, Bahia; CE, Ceará; DF, Distrito Federal; ES, Espírito Santo; GO, Goiás; MA, Maranhão; MG, Minas Gerais; MS, Mato Grosso do Sul; MT, Mato Grosso; PA, Pará; PB, Paraíba; PE, Pernambuco; PI, Piauí; PR, Paraná; RJ, Rio de Janeiro; RN, Rio Grande do Norte; RO, Rondônia; RR, Roraima; RS, Rio Grande do Sul; SC, Santa Catarina; SE, Sergipe; SP, São Paulo; TO, Tocantins.
Demographic characteristics and comorbidities among COVID-19 survivors and non-survivors.
|
|
| |
|---|---|---|
|
|
| |
| North ( | 106,266 (53.3%) | 93,019 (46.7%) |
|
| ||
| 14–50 ( | 44,201 (75.2%) | 14,546 (24.8%) |
| 51–100 ( | 62,064 (44.2%) | 78,474 (55.8%) |
|
| ||
| Women ( | 48,182 (54.6%) | 40,043 (45.4%) |
| Men ( | 58,084 (52.3%) | 52,976 (47.7%) |
|
| ||
| White ( | 14,757 (50.9%) | 14,241 (49.1%) |
| Mixed-race ( | 848,85 (53.8%) | 72,791 (46.2%) |
| Black ( | 4,281 (50.5%) | 4,200 (49.5%) |
| Asian ( | 1,642 (58.2%) | 1,179 (41.8%) |
| Indigenous ( | 701 (53.6%) | 608 (46.4%) |
|
| ||
| Renal disease ( | 2,405 (33.1%) | 4,871 (66.9%) |
| Liver disease ( | 586 (36.1%) | 1,037 (63.9%) |
| Immunosuppression ( | 1,822 (43.1%) | 2,406 (56.9%) |
| Obesity ( | 5,366 (48.7%) | 5,651 (51.3%) |
| Neurological disease ( | 1,761 (36.0%) | 3,129 (64.0%) |
| Pulmonary disease ( | 1,663 (35.8%) | 2,985 (64.2%) |
| Hematologic disease ( | 530 (44.2%) | 668 (55.8%) |
| Diabetes ( | 22,397 (44.7%) | 27,749 (55.3%) |
| Cardiovascular disease ( | 27,351 (45.0%) | 33,483 (55.0%) |
| Central-South ( | 402,500 (62.8%) | 238,416 (37.2%) |
|
| ||
| 14–50 ( | 152,460 (82.9%) | 31,389 (17.1%) |
| 51–100 ( | 250,040 (55.1%) | 207,027 (44.9%) |
|
| ||
| Women ( | 183,063 (63.5%) | 105,320 (36.5%) |
| Men ( | 219,437 (62.2%) | 133,096 (37.8%) |
|
| ||
| White ( | 256,977 (63.3%) | 149,169 (36.7%) |
| Mixed-race ( | 118,534 (62.9%) | 69,921 (37.1%) |
| Black ( | 21,438 (56.9%) | 16,244 (43.1%) |
| Asian ( | 4,870 (64.2%) | 2,721 (35.8%) |
| Indigenous ( | 681 (65.4%) | 361 (34.6%) |
|
| ||
| Renal disease ( | 9,464 (39.9%) | 14,235 (60.1%) |
| Liver disease ( | 2,379 (43.8%) | 3,047 (56.2%) |
| Immunosuppression ( | 7,352 (47.5%) | 8,117 (52.5%) |
| Obesity ( | 30,364 (56.4%) | 23,481 (43.6%) |
| Neurological disease ( | 9,984 (39.8%) | 15,129 (60.2%) |
| Pulmonary disease ( | 10,856 (43.2%) | 14,278 (56.8%) |
| Hematologic disease ( | 2,290 (50.4%) | 2,250 (49.6%) |
| Diabetes ( | 84,854 (53.5%) | 73,613 (46.5%) |
| Cardiovascular disease ( | 121,774 (54.1%) | 103,463 (45.9%) |
Ethnic characteristics of patients at each stage of hospitalization from COVID-19.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| White | 27.8% | 28,998 | 10,173 | 14,241 | 49.1% | 6,867 | 7,374 |
| Mixed-race | 61.5% | 157,676 | 48,667 | 72,791 | 46.2% | 37,960 | 34,831 |
| Black | 8.8% | 8,481 | 2,880 | 4,200 | 49.5% | 2,139 | 2,061 |
| Asian | 1.2% | 2,821 | 811 | 1,179 | 41.8% | 613 | 566 |
| Indigenous | 0.7% | 1,309 | 194 | 608 | 46.4% | 460 | 148 |
| White | 58.7% | 406,146 | 136,622 | 149,169 | 36.7% | 66,164 | 83,005 |
| Mixed-race | 33.2% | 188,455 | 61,157 | 69,921 | 37.1% | 32,456 | 37,465 |
| Black | 6.8% | 37,682 | 12,655 | 16,244 | 43.1% | 8,076 | 8,168 |
| Asian | 1.1% | 7 591 | 2,564 | 2,721 | 35.8% | 1,175 | 1,546 |
| Indigenous | 0.3% | 1,042 | 295 | 361 | 34.6% | 171 | 190 |
*Census of the Brazilian population.
Figure 3Ethnicity distributions according to number of comorbidities (A,B), age group (C,D).
Model for mortality rates.
|
|
|
|
| |
|---|---|---|---|---|
| Intercept | −1.5534 | 4143.2854 | <0.0001 | |
| Age_less_50_years | −0.8672 | 2678.2748 | <0.0001 | |
| Ethnicity | Non-white | 0.0603 | 128.3516 | <0.0001 |
| Gender | Male | 0.1614 | 1127.7744 | <0.0001 |
| Cardiovascular_disease | 0.1729 | 1114.5035 | <0.0001 | |
| Diabetes | 0.1875 | 1137.8771 | <0.0001 | |
| Hematological_disease | 0.2217 | 59.5684 | <0.0001 | |
| Down_syndrome | 0.2888 | 37.9069 | <0.0001 | |
| Region | Northern | 0.3127 | 2061.7896 | <0.0001 |
| Age_50_years_higher | 0.4106 | 652.1627 | <0.0001 | |
| Obesity | 0.4556 | 2596.4568 | <0.0001 | |
| Illiterate_patient | 0.4566 | 1096.2094 | <0.0001 | |
| Pulmonary_disease | 0.4858 | 1513.6012 | <0.0001 | |
| Liver_disease | 0.5021 | 376.4814 | <0.0001 | |
| Immunosuppresions | 0.5278 | 1157.7189 | <0.0001 | |
| Renal_disease | 0.6774 | 2906.2803 | <0.0001 | |
| Neurological_disease | 0.6880 | 3007.4068 | <0.0001 | |
| I_relative_income* | 0.8959 | 1029.9471 | <0.0001 | |
| Number of observations used | 840,201 |
*I relative income means the inverse of the relative income. The higher that indicator, the worse the individual's economic condition.
Figure 4Social and risk factor indicators that lead to mortality for patients hospitalized with COVID-19.